Improved Speech Intelligibility in Subjects With Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in a Phase 1b Study.

Saved in:
Bibliographic Details
Title: Improved Speech Intelligibility in Subjects With Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in a Phase 1b Study.
Authors: McLean WJ; Frequency Therapeutics, Woburn, MA & Farmington, CT.; Department of Surgery, University of Connecticut School of Medicine, Farmington, CT., Hinton AS; Frequency Therapeutics, Woburn, MA & Farmington, CT., Herby JTJ; Frequency Therapeutics, Woburn, MA & Farmington, CT., Salt AN; Department of Otolaryngology, Central Institute for the Deaf, Fay and Carl Simons Center for Hearing and Deafness, Washington University School of Medicine, Saint Louis, MO., Hartsock JJ; Department of Otolaryngology, Central Institute for the Deaf, Fay and Carl Simons Center for Hearing and Deafness, Washington University School of Medicine, Saint Louis, MO., Wilson S; Frequency Therapeutics, Woburn, MA & Farmington, CT., Lucchino DL; Frequency Therapeutics, Woburn, MA & Farmington, CT., Lenarz T; Department of Otolaryngology and Cluster of Excellence of the German Research Foundation 'Hearing4all', Hannover Medical School, Hannover, Germany., Warnecke A; Department of Otolaryngology and Cluster of Excellence of the German Research Foundation 'Hearing4all', Hannover Medical School, Hannover, Germany., Prenzler N; Department of Otolaryngology and Cluster of Excellence of the German Research Foundation 'Hearing4all', Hannover Medical School, Hannover, Germany., Schmitt H; Department of Otolaryngology and Cluster of Excellence of the German Research Foundation 'Hearing4all', Hannover Medical School, Hannover, Germany., King S; Ear Medical Group., Jackson LE; Ear Institute of Texas, San Antonio, TX., Rosenbloom J; Alamo ENT Associates, San Antonio, TX., Atiee G; Worldwide Clinical Trials, San Antonio, TX., Bear M; Forsythe and Bear LLC, Woodland Hills, CA., Runge CL; Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, WI., Gifford RH; Department of Hearing and Speech Sciences, Vanderbilt University Medical Center, Nashville, TN., Rauch SD; Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear, Boston., Lee DJ; Department of Otolaryngology, Harvard Medical School and Massachusetts Eye and Ear, Boston., Langer R; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA., Karp JM; Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School Boston MA.; Harvard-MIT Division of Health Science and Technology.; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA., Loose C; Frequency Therapeutics, Woburn, MA & Farmington, CT., LeBel C; Frequency Therapeutics, Woburn, MA & Farmington, CT.
Source: Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology [Otol Neurotol] 2021 Aug 01; Vol. 42 (7), pp. e849-e857.
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 100961504 Publication Model: Print Cited Medium: Internet ISSN: 1537-4505 (Electronic) Linking ISSN: 15317129 NLM ISO Abbreviation: Otol Neurotol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1537-4505
DOI:10.1097/MAO.0000000000003120